In depth
Inflammatory myositis and blood tests
Creatine kinase is the test people with myositis watch, and it's the one that gets discussed at every single visit. The test that predicts the dangerous complication here is a different one altogether. Both are worth understanding separately, because they answer questions that don't overlap much at all.
What the research found.
In anti-MDA5 dermatomyositis, lactate dehydrogenase came out among the strongest blood tests anybody has looked at here. It separated the people who went on to develop fast-moving interstitial lung disease from those who didn't, at a mean difference of 75.94. The true value ranges from 64.20 to 87.67.
In that review two other markers were much weaker, with AST at a mean difference of 24.35 and ALT at 26.20. Both of those sit a long way behind LDH. Two clinical predictors also was notable, with fever at an odds ratio of 3.16, from 2.12 to 4.72, and a positive anti-Ro-52 at 2.87, from 1.52 to 5.40.
Hard weight training in myositis raised no disease activity anywhere across 16 weeks, and creatine kinase didn't spike either. Muscle endurance improved by 11.49 points between the training group and the controls, and manual muscle testing improved by 1.30. Neither of those gains came with a laboratory signal of damage.
That trial followed people for a year afterward, which is unusual for an exercise trial in a rare disease. At one year the muscle endurance gain between groups was 10.7 points, on a true value ranging from 2.2 to 19.1. The safety picture was unchanged at that point.
What the number means.
| Test | What it measures | What it's useful for | What it can't do |
|---|---|---|---|
| Creatine kinase | An enzyme released from damaged muscle | Following muscle involvement over time | Distinguish disease activity from unaccustomed exertion on one reading |
| Lactate dehydrogenase | An enzyme released from many tissues, including lung | Discriminating rapidly progressive lung disease in anti-MDA5 disease, at 75.94 | Stand alone. Fever and antibody status contribute too |
| AST and ALT | Enzymes from liver and muscle | Supporting a picture of tissue injury, at 24.35 and 26.20 | Match LDH as discriminators, and they're often assumed to be liver tests |
| Anti-MDA5 | An antibody defining a specific subgroup | Identifying the group at risk of rapidly progressive lung disease | Be described further here. We hold no source on its test performance |
| Anti-Ro-52 | An antibody appearing alongside others | Predicting rapidly progressive lung disease at an odds ratio of 2.87 | Tell you its sensitivity or specificity. A prognostic odds ratio isn't a test accuracy figure |
| Creatine kinase after exercise | The same enzyme after exertion | Reassurance: 16 weeks of high-intensity training produced no spike | Be read without knowing what somebody has been doing |
A reference range is not a target. Where a range on this page differs from the one your laboratory prints, the difference is explained above and sourced below. Where no trial has tested a target, this page says so rather than offering one.
Two tests, and the less watched one counts more
Creatine kinase is the test people with myositis follow, and it's the one that gets discussed at every visit. It's an enzyme that comes out of damaged muscle, so following it over time is a fair way to track how the muscles are doing. That much is uncontroversial, and it isn't the whole story.
The laboratory finding with the most at stake in this disease is a different one entirely. In anti-MDA5 dermatomyositis, lactate dehydrogenase was notable among the strongest markers for fast-moving interstitial lung disease, at a mean difference of 75.94. The true value ranges from 64.20 to 87.67, which is a wide spread between the people who went on to develop it and the people who didn't.
That form of lung disease kills a high share of the people who get it. So the test worth understanding most carefully is the one that speaks to the lungs, not the one that speaks to the muscles. That's close to the reverse of where most of the attention goes.
What creatine kinase can and can't tell you
Creatine kinase rises when muscle is damaged, and disease damages muscle, and so does hard effort. That's the whole difficulty with reading a single result. An unaccustomed session of exercise raises it in people who have no muscle disease at all.
The trial that looked at this specifically is reassuring, because hard weight training in myositis raised no disease activity over 16 weeks. Creatine kinase didn't spike, muscle endurance improved by 11.49 points between the groups, and manual muscle testing improved by 1.30 points on that comparison. At one year the between-group endurance gain was 10.7 points and the safety picture was unchanged.
The question people ask is whether exercise sends creatine kinase up, and in that trial it didn't. What a rise means in your own case is a different question, and it needs reading against your symptoms, your exam, and what you've been doing lately. That's what your team is for, because one number on its own is a poor basis for deciding alone.
The lung complication and the numbers behind it
One review looked for predictors of fast-moving interstitial lung disease in anti-MDA5 dermatomyositis. It found lactate dehydrogenase among the strongest blood tests, at a mean difference of 75.94, with a confidence interval ranging from 64.20 to 87.67. That range doesn't touch zero, so the difference is real rather than chance.
Other tissue injury markers were much weaker, with AST at a mean difference of 24.35 and ALT at 26.20. Both are real separations, and both sit a long way behind LDH. Two clinical predictors was notable as well, with fever at an odds ratio of 3.16, from 2.12 to 4.72, and a positive anti-Ro-52 at 2.87, from 1.52 to 5.40.
Our record for that paper says the full text is worth getting, and it calls the paper the highest-stakes item in the myositis source set. Not all of its individual values got captured. What this page quotes are the figures the record holds verbatim, and the review notes ask for the full text before sign-off.
Why a raised AST isn't automatically your liver
AST and ALT often get called liver tests, and both come out of muscle as well as liver. In a person with a muscle disease, a raised AST is at least as likely to be muscle as liver. That's standard biochemistry rather than anything peculiar to myositis at all.
It counts because it changes what happens next, in that a raised AST read as a liver result leads to liver tests. In somebody with active myositis, that may be looking in the wrong place. They turned up in the lung disease review at 24.35 and 26.20, so they hold some information about this disease.
That doesn't mean a liver problem is impossible. It does mean the reading needs the muscle disease in the frame, and raising that explicitly with whoever ordered the test is reasonable. A liver referral that goes unquestioned is a slower route to the answer you'd get anyway.
What the antibodies change
Anti-MDA5 marks out one group within dermatomyositis, and that's the group where fast-moving interstitial lung disease happens. That group is why this page takes the form it does. A positive anti-Ro-52 predicted that complication too, at an odds ratio of 2.87 from 1.52 to 5.40, and neither result says anything about how much muscle strength somebody has today.
Those results change how closely the lungs get watched. They don't change how the muscles get treated, and somebody who is anti-MDA5 positive appears in a different monitoring category from somebody who isn't. Understanding which category you're in is a good deal more useful than filing the result away under a label.
This site holds no source on how well either antibody performs as a test, which is a real hole on a page about blood tests. It also holds nothing on the myositis antibody panel as a whole, which is how these diseases now get sorted into groups. Those absences are named rather than filled with estimates.
What to watch for yourself
Breathing comes first, and new or worse breathlessness needs prompt assessment. So does a new cough, because neither one waits for a routine visit. In this disease group, interstitial lung disease is what decides the outlook, and the rapidly progressive form moves fast.
Fever is worth mentioning for the reason above, at an odds ratio of 3.16 in the review of that complication. It's an easy symptom to attribute to something incidental. Mentioning it costs a phone call, and misattributing it can cost a great deal more than that.
Muscle symptoms are the less urgent half of the picture, which is an uncomfortable thing to say on a page about a muscle disease. Three changes are worth mentioning by name, which are trouble getting out of a chair, trouble on stairs, and trouble lifting overhead. They'll be read alongside your creatine kinase rather than instead of it.
Common misconceptions.
Myth. A rising creatine kinase means my disease is flaring.
Reality. It may, though one reading can't tell two things apart. It can't split disease activity from unusual effort, and creatine kinase rises after exercise in people with no muscle disease at all. One trial looked at this, and over 16 weeks hard weight training produced no spike, so take a rise to your team rather than deciding what caused it yourself.
Myth. Creatine kinase is the number that counts most in this disease.
Reality. It's the one most watched, but the blood test with the most at stake is lactate dehydrogenase. In anti-MDA5 disease, LDH separated fast-moving interstitial lung disease at a mean difference of 75.94, with AST far behind at 24.35 and ALT at 26.20. That form of the disease kills a high share of the people who get it, which is what gives the number weight.
Myth. AST and ALT being raised means my liver is affected.
Reality. They come out of muscle as well as liver, which is why they rise in muscle disease and why they get misread as liver tests. In the review of fast-moving lung disease they came out at 24.35 and 26.20. So they hold information here, a good deal less than LDH does, and a raised AST in myositis isn't automatically a liver problem.
Myth. My antibody result is just a label.
Reality. Anti-MDA5 marks out the group where fast-moving interstitial lung disease happens, and that form kills a lot of people. A positive anti-Ro-52 predicted it at an odds ratio of 2.87, and those are the results that change how closely somebody's lungs get watched. Neither figure is a test accuracy result, and how many cases either antibody catches, or how many healthy people it clears, has never been published.
Questions patients ask.
What does my creatine kinase result mean?
It's an enzyme that comes out of damaged muscle, and it's the test most followed in this disease. What one reading can't do is tell two things apart, because it can't split disease activity from unusual effort. Creatine kinase rises after exercise in people with no muscle disease at all. One trial looked at this, and over 16 weeks hard weight training produced no spike.
So is a rise after exercise a problem?
Not automatically, so mention it rather than trying to decide about it yourself. One randomized trial gave hard weight training in myositis, and over 16 weeks disease activity didn't rise and creatine kinase didn't spike. Muscle endurance improved by 11.49 points and manual muscle testing improved by 1.30 points. Your team can read a rise against your symptoms, your exam, and what you've been doing lately.
Why does lactate dehydrogenase get measured?
Because in anti-MDA5 dermatomyositis it is notable among the blood tests. It's among the strongest for spotting fast-moving interstitial lung disease, at a mean difference of 75.94 on a true value from 64.20 to 87.67. That form of lung disease kills a lot of people, so LDH is the blood test with the most at stake here.
What else predicts the lung complication?
In that review AST came out at 24.35 and ALT at 26.20, both sitting far behind LDH. Two clinical predictors was notable, with fever at an odds ratio of 3.16, from 2.12 to 4.72, and a positive anti-Ro-52 at 2.87, from 1.52 to 5.40. Our record for that paper says the full text is worth getting, and it calls the paper the highest-stakes item in the myositis source set. So these figures are the ones it holds word for word.
My AST is raised. Is that my liver?
Not necessarily, because AST and ALT come out of muscle as well as liver. That's why they rise in a muscle disease, and it's also why they so often get misread as liver tests. In the lung disease review they came out at 24.35 and 26.20. A raised AST in somebody with myositis needs reading in that light rather than as a liver result on its own.
What does my antibody result change?
Anti-MDA5 marks out one group, and it's the group where fast-moving interstitial lung disease happens. That form kills a lot of people, and a positive anti-Ro-52 predicted it too, at an odds ratio of 2.87 from 1.52 to 5.40. Those results change how closely lungs get watched rather than how muscles get treated. Both are links to outcome rather than test accuracy, and how many cases either antibody catches, or how many well people it clears, has never been published.
What should I be watching for myself?
Breathing comes first, above everything else on this list. New or worse breathlessness needs prompt assessment and so does a new cough, because neither one waits for a routine visit. In this disease group, interstitial lung disease is what decides the outlook. Fever is worth mentioning too, at an odds ratio of 3.16 in that review, and muscle symptoms are the less urgent half of the picture.
References.
- Liu T; Ji X; Wei Y et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis. Rheumatology (Oxford, England). 2026;65. 10.1093/rheumatology/keag311Systematic review and meta-analysis of 27 cohorts
- Jensen KY; Aagaard P; Suetta C et al. High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial. Rheumatology international. 2024;44:1909-1921. 10.1007/s00296-024-05698-yRCT
- Jensen KY; Aagaard P; Suetta C et al. High-intensity resistance training in patients with myositis - 1-year follow-up on a randomised controlled trial. Rheumatology international. 2025;45:104. 10.1007/s00296-025-05858-8RCT follow-up
- da Silva BISL; Dos Santos BRJ; Carneiro JA et al. Physical exercise for dermatomyositis and polymyositis: a systematic review and meta-analysis. Clinical rheumatology. 2022;41:2635-2646. 10.1007/s10067-022-06281-1SR + MA
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.
Across the site